Fig. 3

ICI blocks the 2′,3′,4′-THC/E2 combination activation of the synergistic and reprogrammed genes. A, B, C Verification of synergistic genes from the microarray in U2OS-ERα cells treated with 10 nM E2, 5 μM 2′,3′,4′-THC, and 1 μM ICI alone or in combination for 24 h. A KRT 19, B OTOF, and C MSMB mRNA levels were measured by qRT-PCR. D, E, F Verification of reprogrammed genes from the microarray in U2OS-ERα cells treated with 10 nM E2, 5 μM 2′,3′,4′-THC, and 1 μM ICI alone or in combination for 24 h. D K6iRS3, E FGR, and F UBD mRNA levels were measured by qRT-PCR. G, H, I U2OS-ERα cells were treated with increasing doses of E2 in the absence and presence of 5 μM 2′,3′,4′-THC for 24 h. G KCNK6, H K6iRS3, and I FGR mRNA levels were measured by qRT-PCR. GAPDH was used as a reference gene to calculate fold change. The data are mean of triplicate samples ± SD. The statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons post hoc test